| Literature DB >> 30222164 |
Ulrich Jarry1, Noémie Joalland1, Cynthia Chauvin1, Béatrice Clemenceau2, Claire Pecqueur1, Emmanuel Scotet3.
Abstract
Glioblastoma multiforme (GBM), the most frequent and aggressive primary brain cancer in adults, is generally associated with a poor prognosis, and scarce efficient therapies have been proposed over the last decade. Among the promising candidates for designing novel therapeutic strategies, cellular immunotherapies have been targeted to eliminate highly invasive and chemo-radioresistant tumor cells, likely involved in a rapid and fatal relapse of this cancer. Thus, administration(s) of allogeneic GBM-reactive immune cell effectors, such as human Vϒ9Vδ2 T lymphocytes, in the vicinity of the tumor would represents a unique opportunity to deliver efficient and highly concentrated therapeutic agents directly into the site of brain malignancies. Here, we present a protocol for the preparation and the stereotaxic administration of allogeneic human lymphocytes in immunodeficient mice carrying orthotopic human primary brain tumors. This study provides a preclinical proof-of-concept for both the feasibility and the antitumor efficacy of these cellular immunotherapies that rely on stereotactic injections of allogeneic human lymphocytes within intrabrain tumor beds.Entities:
Mesh:
Year: 2018 PMID: 30222164 PMCID: PMC6235084 DOI: 10.3791/57870
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355